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Abstract
The term "translational research" is used to describe the transfer of basic biological knowledge into
practical medicine, a process necessary for motivation of public spending. In the area of cancer
therapeutics, it is becoming increasingly evident that results obtained in vitro and in animal models
are difficult to translate into clinical medicine. We here argue that a number of factors contribute
to making the translation process inefficient. These factors include the use of sensitive cell lines and
fast growing experimental tumors as targets for novel therapies, and the use of unrealistic drug
concentrations and radiation doses. We also argue that aggressive interpretation of data, successful
in hypothesis-building biological research, does not form a solid base for development of clinically
useful treatment modalities. We question whether "clean" results obtained in simplified models,
expected for publication in high-impact journals, represent solid foundations for improved
treatment of patients. Open-access journals such as Radiation Oncology have a large mission to
fulfill by publishing relevant data to be used for making actual progress in translational cancer
research.
Background
In a survey of clinical trials of potential anticancer drugs
performed by Nygren and Larsson in 2003 [1], it was con-
cluded that "in earlier phase (trials) no or modest antican-
cer activity was reported" and it was speculated that "the
expanding knowledge in tumour biology might not easily
translate into new substantially better anticancer drugs".
This statement leads to questions of whether the process
of translational research is slower than anticipated, and –
if so – why this might be. One obvious factor is the com-
plexity of biology; we do not yet quite understand all
details with regard to how cancer cells work. How can we
then expect to cure cancer? However, we here argue that
translational cancer research might suffer from shortcom-
ings, in academic laboratories in particular. We discuss a
number of factors which we believe contribute. Our article
is meant to be provocative.
Mice are not men
The French Nobel laureate Jacques Monod remarked in
1965 that "What is true for E. coli is true for an elephant,
only more so." One of the main outcomes of the genomic
sequencing projects is the recognition that many genes,
including those associated with various diseases in
humans, are evolutionary conserved from yeast to man.
Genomic sequence comparisons have revealed that 61%
of Drosophila melanogaster and up to 97% mouse genes are
similar to human genes. Many of the mechanisms devel-
oped by prokaryotic and eukaryotic cells to use energy,
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regulate gene expression and respond to environmental
challenges utilize similar basic biochemical processes.
However, and significantly, there are important differ-
ences between mouse and human cells. Biological mech-
anisms that control life span (replicative senescence) and
apoptosis are not perfectly conserved. It is well known
that mouse cells easily become immortalized in culture,
whereas human cells do not. More recent studies have
shown that p53, p16(INK4a), and telomere regulatory
functions appear to be differentially regulated during rep-
licative senescence in human and mouse fibroblasts [2].
To which extent premature senescence contributes to the
anti-tumorigenic effects of radiation therapy and of vari-
ous drugs is unknown. If senescence in fact is important,
the fact that the mechanism(s) of senescence are not well
conserved between mouse and human cells is a concern.
Many of the currently used anticancer drugs induce apop-
tosis of cancer cells, and identification of apoptosis-induc-
ing compounds is of high priority. The control of
apoptosis appears to differ between mouse and human
cells: BAX knock-out human cells are generally insensitive
to anticancer drugs and to radiation [3-5], whereas it
appears to be necessary to knock-out both BAX and BAK
to achieve the same degree of insensitivity in mouse cells
[6]. Why this is so is unclear. What is clear is that mouse
fibroblasts grown in monolayer on plastic dishes are not
good models for 3-D human tumors proliferating under
(often) hypoxic conditions in vivo.
Treatment-sensitive models are widely used in 
preclinical studies
There are fundamental differences between mouse tumor
models and human cancers. Mouse tumors grow very fast
and are very angiogenesis dependent. Human tumors do
not grow fast and are probably less dependent on angio-
genesis. Drugs such as doxorubicin and cisplatin have pal-
liative effects, at best, in patients with recurrent carcinoma
but often show very strong activities in xenograft-bearing
mice. To make matters worse, treatment-sensitive cell
lines are often used in preclinical models. An example is
the widespread use of the supersensitive Colo205 cell line
in studies of TRAIL.
The use of sensitive models is understandable. It is neces-
sary to demonstrate "proof-of-principle" with regard to
treatment strategy. It is remarkable, however, that it is suf-
ficient to present preliminary results on treatment effi-
ciency obtained in highly sensitive models for publication
in high impact journals. At the same time, these journals
will not publish studies using small clinical materials (<
100 patients), regardless of whether interesting new con-
cepts are presented.
Irrelevant endpoints are widely used in 
preclinical studies
Effects of anticancer drugs in pre-clinical models (e.g.
xenografts) are often evaluated as retarded growth relative
to non-treated control mice. From a clinical perspective,
such retarded growth nevertheless represents progressive
disease. The commonly accepted clinical end-point is pro-
longed over-all survival in patients. Although mice have
shorter life-spans, it is not difficult to set up relevant end-
points also in animal experiments.
Extreme and irrelevant treatment conditions 
are widely used in preclinical studies
In many experiments, animals are treated with drugs only
days after injection of tumor cells. Such experiments
assess drug effects on tumor-take, which is very remote
from the clinical situation aiming at tumor regression.
Even more remote from clinical realities is the occasional
habit of injecting the drug under study into the injection
site.
In our hunt for positive results, we often use drug concen-
trations and radiation doses that are unrealistic. In vitro
drug concentrations in the high micromolar range are
often used. Remarkably, it is often claimed that drugs,
even at these concentrations, have single targets. At the
same time, most researchers are aware of the problems of
unspecific effects using pharmacological inhibitors at
more than 5 – 10 µM. It is difficult to accept the concept
of a single target when a drug is used at concentrations of
50 – 100 µM. Such concentrations are often used for
DNA-damaging drugs. In one study, 500 µM N-methyl-
N'-nitro-N-nitrosoguanidine was used to induce alkylat-
ing DNA damage, a treatment leading to necrotic cell
death [7]. It is very likely that the drug has other targets
than DNA at this concentration. The same problems occur
in the radiation therapy field. Ionizing radiation clearly
induces apoptosis of lymphoid cells. Whether radiation
therapy induces acute apoptosis of epithelial cells is, how-
ever, controversial [8]. In order to induce apoptosis of car-
cinoma cells, investigators use fractions of > 10 Gray. We
have found reports using doses of 40 Gray in high-ranking
journals.
High drug doses are not only used in vitro, but also in ani-
mal models. Drug doses of 100 mg/kg are not uncom-
monly used in xenografts models. The highest
concentration we found in a rapid survey of recent litera-
ture is 1,200 mg/kg. This corresponds to 840 ml intraperi-
toneal infusion of a 10% solution into a 70 kg patient.
Another example is betulinic acid, used at 250 mg/kg to
treat mice with melanoma xenografts [9]. Betulinic acid is
not in clinical use, and treatment of malignant melanoma
is still an unmet medical need. Mice are unable to object
to being treated with very high concentrations and vol-Publish with BioMed Central    and   every 
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umes of toxic compounds. In mice, toxicity is generally
measured as weight loss (typically > 10%) over a limited
time period, whereas more sophisticated measures of tox-
icity are used in humans.
Aggressive interpretation of data
Many scientists in academia choose to interpret their data
quite aggressively. This kind of selective approach may be
a successful strategy in hypothesis-building biological
research, but does not form a solid foundation for devel-
opment of clinically useful treatments. There is always a
danger that investigators may become devoted to a partic-
ular drug, risking to ignore its shortcomings. The develop-
ment of a drug is a fairly standardized procedure, with
extensive ADME (adsorption, distribution, metabolism,
and excretion toxicology) studies. Such studies cannot be
subjected to aggressive interpretation.
How can the translational process become more effective?
Most of us are aware of the problems discussed above, and
realize that they impair the process of translational
research. One way could be to increase the awareness of
journal editors that straightforward papers do not neces-
sarily reflect the complexity of biological systems. As long
as "clear results" are presented, high-ranking journals are
obviously not always concerned about printing reports
where bizarre drug concentrations are used, or where
mouse fibroblasts are used as targets for treatment. Since
publication in these journals is likely to secure grants for
many years, there is an obvious risk that public spending
is not used for realistic projects.
Are academic labs suitable for drug development? Both
yes and no. Academic laboratories have been successful in
providing molecular understanding of sensitivity and
resistance necessary for developing new compounds. Aca-
demic laboratories have been able to develop anticancer
drugs, notably Imatinib for CML. Solid carcinomas are
more difficult in terms of more complex targets (i.e. less
dependence on one pathway) and of delivery to tumor
cells (i.e. ADME). This increased complexity may be diffi-
cult to handle for academic groups.
The public expects the cancer research community to cure
cancer in humans, and probably care less about cancer in
small rodents. It is nevertheless easier to publish papers
using knock-out mouse fibroblasts than papers using
human tumor cells. We feel that open-access journals
such as Radiation Oncology have a large mission to fulfill;
to be a role model for publishing relevant data, for open
discussion of data and how to use data for making actual
progress in translational cancer research. In a longer per-
spective this will hopefully lead to improvements in the
relevance of the data produced.
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